# MEDORA Integrated Health System — Comprehensive Audit and Readiness Note

**Date:** 15 August 2026  
**Scope:** Internal technical, security, operational, healthcare-workflow, and regulatory-readiness review. Government and regulated external connectors are intentionally deferred until formal approval, specifications, credentials, sandbox access, and acceptance evidence are supplied.

> This document records what was inspected or implemented inside the repository. It is not a legal, medical, cybersecurity, EDA, UPA, GAHAR, or governmental certification.

## Executive outcome

MEDORA is in a stronger position for a controlled institutional and investor showcase. The review covered tenant isolation, session revalidation, audit signing, Investor Showcase simulation, offline-storage boundaries, CSRF and proxy-header handling, AI Markdown rendering, NLM ICD-10-CM reference caching, and frontend vendor splitting.

The latest verification completed successfully with **90 test files passing, 301 tests passing, and 5 tests safely skipped**. TypeScript compilation and the production build passed. The largest frontend vendor chunk is approximately 478.81 KB before compression and 141.13 KB after gzip.

## Implemented controls

| Area | Verified implementation | Status |
|---|---|---|
| Authentication and sessions | Revalidation of user, credential, membership, branch, jurisdiction, environment, and expiry on every request | Implemented and tested |
| Investor Showcase | Isolated organization, branch, account, synthetic data, server-side mutation guard, simulation audit event | Implemented and tested |
| Audit trail | Independent `AUDIT_SIGNING_KEY`, fail-closed validation, normalized inputs, serialized writes | Implemented and tested |
| Tenant isolation | Organization, branch, jurisdiction, membership, and environment checks | Implemented and tested |
| Offline storage | Regulated drafts denied; common PHI, clinical identifiers, credentials, and unsafe legacy drafts blocked or cleaned | Implemented and tested |
| CSRF and proxy headers | Forwarded host/protocol trusted only through the configured loopback proxy | Implemented and tested |
| AI assistant rendering | Raw HTML disabled; HTTPS links restricted; untrusted images blocked; sanitization retained | Implemented and tested |
| NLM ICD-10-CM | Scoped reference search, provenance, version, retrieval/expiry metadata, rate-limited admin refresh | Implemented and tested |
| Performance | Safe Vite vendor code splitting | Implemented and tested |
| Government connectors | Not activated; fail-closed by design | Deferred intentionally |

## Investor Showcase boundary

The showcase is an isolated simulation environment inside the same website, not a window into production. Showcase actions must not change production sales, inventory, balances, claims, or other persistent production records. The server-side guard is authoritative; hiding buttons in the user interface is not considered a security control. The interface should continue to display clear Arabic and English simulation labels.

The showcase must use synthetic data only, must not expose PHI or real supplier/customer data, and must block export, deletion, sensitive connectors, notifications, and irreversible operations. The account uses a managed strong password; weak `test/test` credentials are not acceptable for production access.

## Healthcare and operational readiness

The system includes internal workspaces for pharmacy operations, inventory, sales, supply chain, hospitals, patients, appointments, encounters, referrals, admissions, beds, clinical orders, payers, authorizations, claims, settlements, grievances, quality, and GAHAR readiness. The ICD-10-CM connector is reference-only and does not create a final diagnosis, claim, dispensing decision, or financial mutation automatically.

Production clinical use still requires review and acceptance by qualified physicians, pharmacists, quality officers, technical security staff, and legal/privacy stakeholders. The platform must not be presented as a replacement for clinical judgment, pharmacist review, or facility governance.

## Privacy and governance requirements before live operation

The organization must complete a data classification and DPIA process, retention and deletion rules, data-subject request procedures, incident-response plans, backup restoration tests, processor/hosting contracts, key-management procedures, device and offline-use policies, and role-by-role acceptance testing. These governance controls cannot be proven by source code alone.

## Dependency audit status

The latest `pnpm audit --prod --json` summary reported **3 high, 4 moderate, 2 low, and 0 critical vulnerabilities**. Multiple advisory paths may be represented under the summary. Remaining paths include `path-to-regexp`, `qs`, and `body-parser` through Express 4, plus indirect UI/tooling paths involving packages such as Lodash, Mermaid/Recharts, nanoid, uuid, and mdast utilities.

No blind major upgrade was applied. Express 4.21.2 pins exact transitive versions, so a safe remediation requires an upstream-compatible fix or a separately tested Express 5 migration. The remaining dependency risk must be tracked explicitly and either remediated or formally accepted before unrestricted production deployment.

## Egypt and wider Arabic-region readiness

Official evidence and boundaries are recorded in `docs/audits/regulatory-evidence-2026-08-15.md`. EDA, UPA, GAHAR, tax, insurance, and other government or regulated integrations remain disabled because no approved API contract, credentials, sandbox, security requirements, and acceptance evidence have been supplied. This is an intentional product boundary, not a hidden claim of integration.

For other Arabic jurisdictions, each country requires its own configurable profile covering regulators, product registration, prescriptions, inventory, privacy, taxes, serialization and recalls, laboratory and hospital requirements, language, calendar, currency, and units. Egyptian rules must not be presented as universal Arabic compliance.

## Presentation decision

MEDORA is suitable for a controlled investor and institutional showcase of its internal capabilities. It can be demonstrated to pharmacies, pharmacy chains, distributors, hospitals, laboratories, manufacturers, and public-sector stakeholders as an internally secured platform with deferred external integrations.

It must not yet be described as officially certified, government-connected, GAHAR-accredited, legally compliant in every Arabic country, or unconditionally ready for unsupervised clinical production. Independent penetration testing, SAST/DAST, backup restoration, tenant-conflict testing, formal role review, real recovery-channel activation, and user acceptance testing remain required for live deployment.

**Supporting evidence:** Arabic report: `medora-comprehensive-audit-2026-08-15.md`; regulatory evidence: `regulatory-evidence-2026-08-15.md`; portal review: `showcase-portal-review-final.md`.
